Promising Tolerability and Efficacy Results from Dose-Escalation in an Ongoing Phase Ib/II Study of Mosunetuzumab with Polatuzumab Vedotin (Pola) in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

被引：0

作者：

Budde, Elizabeth ^{[1
]}

Ghosh, Nilanjan ^{[2
]}

Chavez, Julio ^{[3
]}

Lossos, Izidore S. ^{[4
]}

Mehta, Amitkumar ^{[5
]}

Dorritie, Kathleen ^{[6
]}

Kamdar, Manali ^{[7
]}

Negricea, Raluca ^{[8
]}

Song Pham ^{[8
]}

Hristopoulos, Maria ^{[9
]}

Huw, Ling-Yuh ^{[9
]}

O'Hear, Carol ^{[9
]}

Oki, Yasuhiro ^{[9
]}

To, Iris ^{[9
]}

Diefenbach, Catherine ^{[10
]}

机构：

[1] City Hope Natl Med Ctr, Duarte, CA USA

[2] Levine Canc Inst Atrium Hlth, Hematol Oncol & Blood Disorders, Charlotte, NC USA

[3] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[4] Univ Miami Hlth Syst, Sylvester Comprehens Canc Ctr, Miami, FL USA

[5] Univ Alabama Birmingham, ONeal Comprehens Canc Ctr, Birmingham, AL USA

[6] UPMC Hillman Canc Ctr, Pittsburgh, PA USA

[7] Univ Colorado, Ctr Canc, Aurora, CO USA

[8] F Hoffmann La Roche Ltd, Basel, Switzerland

[9] Genentech Inc, San Francisco, CA 94080 USA

[10] NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY USA

来源：

关键词：

ABCL; mosunetuzumab; polatuzumab vedotin; relapsed/refractory; B-NHL; dose-escalation;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ABCL-351

引用

页码：S393 / S394

页数：2